Table 1 Distribution of the studied patients by their demographic and clinicopathological
From: Neoadjuvant chemotherapy for stage II–III breast cancer: a single-center experience
Variables | Patients (n = 147) |
|---|---|
Age in years, mean ±SD | 47.7 ± 10.5 |
< 40 years | 98 (66.7%) |
> 40 years | 49 (33.3%) |
Menopausal status, no. (%) | |
- Premenopausal | 102 (69.4%) |
- Postmenopausal | 45 (30.6%) |
Pathological grade, no. (%) | |
- Grade I | 14 (9.5%) |
- Grade II | 57 (38.8%) |
- Grade III | 73 (49.7%) |
- Unknown grade | 3 (2%) |
Histological type, no. (%) | |
- Ductal | 132 (89.8%) |
- Lobular | 4 (2.7%) |
- Invasive, nos. | 9 (6.1%) |
- Other | 2 (1.4%) |
TNM stage, no. (%) | |
IIA | 28 (19.0%) |
IIB | 64 (43.5%) |
IIIA | 38 (25.9%) |
IIIB | 17 (11.6%) |
Hormonal receptors, no. (%) | |
- ER-positive | 94 (63.9%) |
- PR-positive | 62 (42.2%) |
- Her-2-positive | 54 (36.7%) |
BC subtypes, no. (%) | |
Luminal A | 21 (14.3%) |
Luminal B | 39 (26.5%) |
HER 2 +ve | 53 (36.1%) |
Triple negative | 34 (23.1%) |
KI67 index, no. (%) | |
< 10 | 45 (41.5%) |
> 10 | 86 (58.5%) |